Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:46 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia
NCT03851081 · Roswell Park Cancer Institute · PHASE1/PHASE2 · withdrawn · last registry update 2022-01-28 · Childhood acute lymphoblastic leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “no accrual” | – | Registry record, Roswell Park Cancer Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD22 in childhood acute lymphoblastic leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-04-06Results posted on the registry: SWOG Cancer Research Network, cyclophosphamide + vincristine sulfate (NCT01925131)
- 2021-04-13Results posted on the registry: M.D. Anderson Cancer Center, Cyclophosphamide + Cytarabine (NCT03488225)
- 2021-04-12Results posted on the registry: M.D. Anderson Cancer Center, Inotuzumab Ozogamicin (NCT03094611)
- 2021-04-12Also stopped (terminated): M.D. Anderson Cancer Center, Inotuzumab Ozogamicin (NCT03094611)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision